$1.24
+0.03 (+2.48%)
Open$1.23
Previous Close$1.21
Day High$1.26
Day Low$1.21
52W High$1.91
52W Low$1.02
Volume—
Avg Volume489.9K
Market Cap95.15M
P/E Ratio—
EPS$-1.41
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+461.3% upside
Current
$1.24
$1.24
Target
$6.96
$6.96
$5.52
$6.96 avg
$10.50
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 14.44M | 13.53M | 15.01M |
| Net Income | -947,825 | -765,390 | -987,033 |
| Profit Margin | -6.6% | -5.7% | -6.6% |
| EBITDA | -1,267,375 | -1,123,871 | -1,333,015 |
| Free Cash Flow | -656,212 | -624,188 | -715,122 |
| Rev Growth | +21.5% | +1.8% | +6.7% |
| Debt/Equity | 0.93 | 0.92 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |